What is Spyre Therapeutics, Inc.'s accrued compensation?

Spyre Therapeutics, Inc. (SYRE) reported accrued compensation of $5.07M in Q1 2026.

How has Spyre Therapeutics, Inc.'s accrued compensation changed year-over-year?

Spyre Therapeutics, Inc.'s accrued compensation increased by 224.6% year-over-year, from $1.56M to $5.07M.

What is the long-term trend for Spyre Therapeutics, Inc.'s accrued compensation?

Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s accrued compensation has grown at a 20.1% compound annual growth rate (CAGR), from $4.59M to $7.94M.

Spyre Therapeutics, Inc. SYRE Accrued Compensation

Accrued Compensation at other companies

Johnson & JohnsonJNJ

$6.76B-4.1%

TG TherapeuticsTGTX

$18.66M+263%

ExelixisEXEL

$87.51M-2.5%

ImmunityBio, Inc.IBRX

——

Halozyme TherapeuticsHALO

——

Other financials

Income statement

See full

Revenue-—

Operating income-$45.6M+14.8%

Net income-$69.0M-54.1%

EPS (diluted)-$0.74-23.3%

Balance sheet

See full

Cash & equivalents$97.2M+100%

Total debt$4.3M-9.6%

Total equity$670.8M+39.0%

Total assets$764.0M+34.1%

Cash flow

See full

Operating cash flow-$57.4M-40.0%

CapEx-—

Free cash flow-$39.4M-26.8%

Valuation

See full

Market cap$7.67B+307%

Profitability

See full

Operating margin-39,428.9%-49,795pp

Net margin-52,939.7%-61,871pp

FCF margin-3,442.8%-3,807pp

Returns & leverage

See full

Return on equity-31.1%-10.7pp

Debt / equity0.1×+0.1×

Current ratio9×+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedSalariesCurrent.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s accrued compensation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s accrued compensation?: Spyre Therapeutics, Inc. (SYRE) reported accrued compensation of $5.07M in Q1 2026.
How has Spyre Therapeutics, Inc.'s accrued compensation changed year-over-year?: Spyre Therapeutics, Inc.'s accrued compensation increased by 224.6% year-over-year, from $1.56M to $5.07M.
What is the long-term trend for Spyre Therapeutics, Inc.'s accrued compensation?: Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s accrued compensation has grown at a 20.1% compound annual growth rate (CAGR), from $4.59M to $7.94M.